

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; le⦠read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
$3.23
Price0.00%
$0.00
$349.558m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$240.912m
+6.9%
1y CAGR-3.0%
3y CAGR-10.1%
5y CAGR-$2.25
+17.6%
1y CAGR+11.5%
3y CAGR+3.2%
5y CAGR$313.669m
$368.033m
Assets$54.364m
Liabilities$25.045m
Debt6.8%
-0.1x
Debt to EBITDA-$202.820m
+5.9%
1y CAGR-3.1%
3y CAGR-13.5%
5y CAGR